amycretin

1 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Oral Weight-Loss Drug Expands Market Rather Than Cannibalizing Sales

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.
LLYNVOGLP-1 drugspharmaceutical competition